

ForPatients

by Roche

Neovascular Age-related Macular Degeneration Diabetic Macular Edema

A clinical study to understand how well certain Roche ophthalmology products work over time in people with age-related macular degeneration (nAMD or wet-AMD) and diabetic macular oedema

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Trial Status
Recruiting

Trial Runs In
16 Countries

Trial Identifier
NCT05476926 MR41927

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products (Faricimab and Port Delivery System with Ranibizumab) in approved retinal indications (neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME]) in routine clinical practice. This study will not provide or make recommendations on use of any products including Roche products; treatment decisions will be determined by the treating physician and must be made independently to the decision to participate in this study. Participation in this study will not change or influence a patient's standard of care in any way.

Hoffmann-La Roche
Sponsor

NCT05476926 MR41927
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
